Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies
Nitin Jain, MD, and Joanna M. Rhodes, MD, MDCS, discuss how various aspects of chronic lymphocytic leukemia (CLL) management are approached, including treatment selection based on prior therapies and patient factors, the use of novel agents such as pirtobrutinib, strategies for relapsed/refractory (R/R) disease, treatment sequencing, and the role of multidisciplinary teams in optimizing patient care and outcomes.
EP. 2: Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL
October 15th 2024Panelists discuss how the choice of prior therapy between BTK inhibitors and BCL2 inhibitors influences subsequent treatment decisions in chronic lymphocytic leukemia (CLL), considering factors such as resistance mechanisms, toxicity profiles, and patient-specific characteristics.
EP. 3: Key Patient-Specific Factors Guiding Treatment Selection in CLL
October 22nd 2024Panelists discuss how various patient-specific factors, including age, comorbidities, performance status, disease aggressiveness, symptoms, and biomarkers, are carefully considered to guide the selection of optimal treatment strategies for individuals with chronic lymphocytic leukemia (CLL).
EP. 4: Tailoring Treatment Approaches for Rapid vs. Slow Disease Progression in CLL
October 22nd 2024Panelists discuss how treatment approaches are tailored differently for patients with rapid, aggressive chronic lymphocytic leukemia progression versus those with slower, less aggressive disease, considering factors such as urgency of intervention, choice of therapy intensity, and long-term management strategies.
